Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024
The company is reaffirming revenue guidance for 2024 of RMB 700 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20 HKD | -3.38% |
|
0.00% | -4.31% |
1st Jan change | Capi. | |
---|---|---|
-4.31% | 851M | |
+1.43% | 94.45B | |
-0.66% | 38.9B | |
-13.57% | 32.56B | |
+71.74% | 28.34B | |
-12.73% | 15.98B | |
-2.15% | 13.82B | |
-13.59% | 11.34B | |
+158.88% | 9.81B | |
-52.04% | 9.67B |